Vitamin-C verdict may spell trouble ahead for multinational Chinese companies
On 14 March, a federal jury in New York found Chinese vitamin-C manufacturer Hebei Welcome Pharmaceutical Co and its parent, North China Pharmaceutical Group Corp, liable for agreeing with other Chinese manufacturers to fix prices in the vitamin-C market.
The jury awarded $54.1m (£35m) in damages to the plaintiffs — purchasers including US food and drink companies, packagers, wholesalers and distributors — an amount that was then trebled by the presiding judge to an award of $162.3m in accordance with federal antitrust laws. Three other Chinese manufacturers involved in the conspiracy reached settlements with the plaintiffs prior to the announcement of the verdict…
If you are registered and logged in to the site, click on the link below to read the rest of the Allen & Overy briefing. If not, please register or sign in with your details below.
News from Allen & Overy
News from The Lawyer
Briefings from Allen & Overy
A new Luxembourg act on the immobilisation of bearer shares and units was published in the Luxembourg Official Gazette on 14 August 2014.
OFAC has issued revised guidance relating to the status of entities owned by individuals or entities whose interests in property are blocked under executive orders.
Analysis from The Lawyer
At the time of its launch Accutrainee was described as a revolutionary change to the training model. Has it proved to be so? Not really.
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.